Co-design of an Enhanced Consumer Engagement Process for health technology assessment.


The Enhanced Consumer Engagement Process is one of the key commitments in the 2022-2027 strategic Agreements with Medicines Australia and the Generic and Biosimilar Medicines Association (GBMA).


The agreement includes commitments which ensure:

  • that Australians can access breakthrough new medicines as early as possible.
  • the delivery of a strong and uninterrupted supply of the medicines Australians use every day.

As part of this process a consumer-led Co-design Working Group (CWG) has been set up to consider how to capture consumer and patient perspectives earlier in the medicines listing process.

The CWG has developed proposed recommendations for enhancing consumer engagement in the HTA processes. These are now available for feedback from consumers, health professionals, industry, and other stakeholders with an interest in HTA.


The consultation process:

The consultation will be accessed online. It opens on 1 March 2024 and closes at 11:59PM on 2 April 2024 (AEDT).  It is open to anyone or representatives from organisations interested in providing feedback to support this co-design project. You must be aged 18 years and over to complete the online consultation.

To participate in the consultation, you must review the proposed recommendations first. You can find them in the consultation document.  The consultation document also includes information on how to access the online consultation.

If you would like to find out more and take part in the consultation of the Enhanced Consumer Engagement Process: HERE

For questions or assistance to participate email:




Lucid Health ConsultingLucid logo

At Lucid Health Consulting we provide expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia and the Asia- Pacific region. With over 30 years of Market Access, Health Economics, Regulatory & Compliance, Pricing & Reimbursement and Health Technology Assessment experience, we have helped many organisations to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian and Asia-Pacific markets.

Let us show you how our strategic approach and highly experienced team can help you achieve market access in Australia. Contact and connect with us today to find out more or if you have any questions.

Contact and connect with us at Lucid Health Consulting today: